X0202 3 2007-05-22 0 0001388775 Sirtris Pharmaceuticals, Inc. SIRT 0001296771 Freund John Gordon C/O SIRTRIS PHARMACEUTICALS, INC. 790 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Series A Redeemable Convertible Preferred Stock Common Stock 1600000 I See Footnote. Series A-1 Redeemable Convertible Preferred Stock Common Stock 3750000 I See Footnote. Series B Redeemable Convertible Preferred Stock Common Stock 1875000 I See Footnote. Series C Redeemable Convertible Preferred Stock Common Stock 1276786 I See Footnote. Series C-1 Redeemable Convertible Preferred Stock Common Stock 1190476 I See Footnote. Non-Qualified Stock Option (Right to Buy) 5.99 2017-03-01 Common Stock 22857 D Immediately exercisable. Not applicable. Consists of 9,456,810 shares held by Skyline Venture Partners Qualified Purchaser Fund III, L.P. and 235,452 shares held by Skyline Venture Partners III, L.P. The general partner of each of the Skyline Funds is Skyline Venture Managent III, LLC, for which Dr. Freund is a Managing Director and therefore has shared control. Dr. Freund disclaims beneficial ownership of shares held by the Skyline funds. Upon the closing of the Issuer's initial public offering, each 5.25 shares of Series A, Series A-1, Series B, Series C, and Series C-1 Redeemable Convertible Preferred Stock, respectively, will automatically convert into 1 share of Common Stock. The options vest as to 33.33% of the shares on each anniversary of March 1, 2007 so long as the Reporting Person continues to serve as a director of Issuer; provided, however, that no vesting shall occur unless the Issurer has completed its initial public offering by the March 1, 2008. /s/ Marc Rubenstein, Attorney-in-fact 2007-05-22